You just read:

OncoSec Announces Positive Phase II Data Demonstrating Company's ImmunoPulse® IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients

News provided by

OncoSec Medical Incorporated

Feb 23, 2017, 11:30 ET